Korean J Med.  2009 Jan;76(1):12-17.

New drugs for Rheumatoid arthritis

Affiliations
  • 1Department of Internal Medicine, Division of Rheumatology, Hallym University Sacred Heart Hospital, Anyang, Korea.

Abstract

Since the late 1990s, based on scientific advancement and biotechnological improvement, many effective drugs such as leflunomide and biologic agents for rheumatoid arthritis (RA) have been developed. These include TNF-alpha inhibitors such as etanercept, infliximab, and adalimumab, a peripheral B-cell depleting agent such as rituximab, CTLA-4 Ig such as abatacept, and IL-1 receptor antagonist such as anakira. These new agents have provided good efficacy in the treatment of patents with severe or refractory rheumatoid arthritis and have provided retardation or prevention of radiographic progression or joint destruction despite some side effects such as tuberculosis, infection, malignancies. In this review, new therapeutic alternatives would be given, and chances for more improved outcomes in the care of patients with rheumatoid arthritis provided.

Keyword

Biologic agent; TNF-alpha inhibitor; anti-B cell therapy; CTLA4; rheumatoid arthritis

MeSH Terms

Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Arthritis, Rheumatoid
B-Lymphocytes
Humans
Immunoconjugates
Immunoglobulin G
Interleukin-1
Isoxazoles
Joints
Receptors, Tumor Necrosis Factor
Tuberculosis
Tumor Necrosis Factor-alpha
Rituximab
Abatacept
Adalimumab
Infliximab
Etanercept
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Murine-Derived
Immunoconjugates
Immunoglobulin G
Interleukin-1
Isoxazoles
Receptors, Tumor Necrosis Factor
Tumor Necrosis Factor-alpha
Full Text Links
  • KJM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2022 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr